Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

head of the HIV Prevention Trials Network says there are four areas of research which are being investigated in HIV; ...

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

Treatment for HIV/AIDS has consistently seen progress each ... The results of the iPrEx study were released in 2010, finding that a daily dose of HIV drugs reduced the risk of HIV infection ...

Dolutegravir is an HIV integrase ... with few treatment discontinuations due to adverse effects. Headache, nausea and diarrhea were the most likely side effects reported in clinical trials.

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Blog - allAfrica's Sethi Ncube is in Lima, Peru, for the 5th HIV Research for Prevention Conference, HIVR4P 2024, reporting ...

they plan to study how it performs when given in conjunction with both antibiotics and cART together. This treatment regimen is standard for patients with both HIV and active TB. Dr. Mehra said ...

As we advance through 2024, significant updates in Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infections (STI) prevention and treatment are emerging. Recent clinical trials and global ...

Sweden has reached the UNAIDS and WHO targets for the HIV epidemic, according to a study in Eurosurveillance by researchers ...

However, most people living with HIV in the U.S. do not develop AIDS, because effective treatment options are available. Today, when utilizing effective treatment, people with HIV can live long ...